{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:14:25Z","timestamp":1787501665137,"version":"build-2736575974"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:p>\n                    The hepatitis C virus (HCV) core protein is crucial in viral pathogenesis and hepatocarcinogenesis. Amino acid substitutions at position 70, particularly R70Q and R70H, are associated with an increased risk of hepatocellular carcinoma (HCC) and partial resistance to interferon-based therapy in genotype 1b infections. However, the global and temporal dynamics of these oncogenic mutations remain poorly understood. In this study, we analyzed 3,218 publicly available HCV subtype 1b core sequences to investigate the global distribution of R70Q\/H mutations and their evolution across therapeutic eras. Our findings reveal notable regional disparities, with R70Q prevalence highest in Western Europe (77.4%) and Northern America (70.4%), while R70H was most frequent in Central America (45%). Temporal analysis of 1,351 dated sequences showed a significant decline in R70Q\/H frequency during the pegylated interferon plus ribavirin era (2001\u20132010: 24%) compared to the conventional interferon period (1989\u20132000: 39%;\n                    <jats:italic>p<\/jats:italic>\n                    = 0.0081), followed by a resurgence in the direct-acting antivirals (DAAs) era (2014\u2013present: 43%;\n                    <jats:italic>p<\/jats:italic>\n                    = 0.0183). These temporal shifts, including both the decline and resurgence, suggest a complex interplay between treatment-related selective forces, viral diversity, host factors, and possibly sampling bias. Our results underscore the need for regional molecular surveillance to guide HCC monitoring in HCV subtype 1b patients with R70Q\/H mutations, even after viral clearance, and to inform targeted prevention strategies in high-prevalence areas.\n                  <\/jats:p>","DOI":"10.3389\/fcimb.2025.1619865","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T05:34:57Z","timestamp":1756791297000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Global distribution and temporal analysis of R70Q\/H oncogenic mutations in hepatitis C virus subtype 1b core protein"],"prefix":"10.3389","volume":"15","author":[{"given":"Gabriela T. M.","family":"Nunes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia M.","family":"Araujo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1002\/jmv.22094","article-title":"Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy","volume":"83","author":"Akuta","year":"2011","journal-title":"J.\u00a0Med. Virol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1128\/JCM.01457-15","article-title":"Impact of Mutations at Amino Acid 70 in Hepatitis C Virus (HCV) Genotype 1b Core Region on Hepatocarcinogenesis following Eradication of HCV RNA","volume":"53","author":"Akuta","year":"2015","journal-title":"J. Clin. Microbiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/jmv.23837","article-title":"Genetic variability of hepatitis B and C viruses in Brazilian patients with and without hepatocellular carcinoma","volume":"86","author":"Araujo","year":"2014","journal-title":"J. Med. Virol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1186\/s12879-019-4514-1","article-title":"Molecular characterization of hepatitis C virus in liver disease patients in Botswana: a retrospective cross-sectional study","volume":"19","author":"Bhebhe","year":"2019","journal-title":"BMC Infect. Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1126\/science.2523562","article-title":"Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome","volume":"244","author":"Choo","year":"1989","journal-title":"Science"},{"key":"B6","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1002\/hep.26205","article-title":"Polymorphisms of the core, NS3, and NS5A proteins of hepatitis C virus genotype 1b associate with development of hepatocellular carcinoma","volume":"58","author":"El-Shamy","year":"2013","journal-title":"Hepatology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1053\/j.gastro.2004.09.014","article-title":"Hepatocellular carcinoma in cirrhosis: incidence and risk factors","volume":"127","author":"Fattovich","year":"2004","journal-title":"Gastroenterology"},{"key":"B8","unstructured":"Ferlay\n              J.\n            \n            \n              Ervik\n              M.\n            \n            \n              Lam\n              F.\n            \n            \n              Laversanne\n              M.\n            \n            \n              Colombet\n              M.\n            \n            \n              Mery\n              L.\n            \n          \n          Global cancer observatory: cancer today. Lyon, France: international agency for research on cancer\n          \n          2024"},{"key":"B9","doi-asserted-by":"publisher","first-page":"5986","DOI":"10.1128\/JVI.02583-10","article-title":"Analysis of interferon signaling by infectious hepatitis C virus clones with substitutions of core amino acids 70 and 91","volume":"85","author":"Funaoka","year":"2011","journal-title":"J. Virol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1111\/j.1349-7006.2009.01338.x","article-title":"Characteristic mutations in hepatitis C virus core gene related to the occurrence of hepatocellular carcinoma","volume":"100","author":"Hu","year":"2009","journal-title":"Cancer Sci."},{"key":"B11","unstructured":"Flaviviridae: hepacivirus C classification\n          \n          2024"},{"key":"B12","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.meegid.2011.01.017","article-title":"Sequence variability of HCV Core region: important predictors of HCV induced pathogenesis and viral production","volume":"11","author":"Khaliq","year":"2011","journal-title":"Infect. Genet. Evol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"7685371","DOI":"10.1155\/2018\/7685371","article-title":"Frequency of interferon-resistance conferring substitutions in amino acid positions 70 and 91 of core protein of the Russian HCV 1b isolates analyzed in the T-cell epitopic context","volume":"2018","author":"Kichatova","year":"2018","journal-title":"J. Immunol. Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1086\/652500","article-title":"Positive selection of core 70Q variant genotype 1b hepatitis C virus strains induced by pegylated interferon and ribavirin","volume":"201","author":"Kurbanov","year":"2010","journal-title":"J. Infect. Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1097\/JCMA.0000000000000965","article-title":"Residual risk of hepatocellular carcinoma development for chronic hepatitis C patients treated by all oral direct-acting antivirals with sustained virological response","volume":"86","author":"Luan","year":"2023","journal-title":"J. Chin. Med. Assoc."},{"key":"B16","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nrmicro1645","article-title":"Replication of hepatitis C virus","volume":"5","author":"Moradpour","year":"2007","journal-title":"Nat. Rev. Microbiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1126\/science.282.5386.103","article-title":"Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy","volume":"282","author":"Neumann","year":"1998","journal-title":"Science"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1002\/jmv.25047","article-title":"Amino acid substitutions in the hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by all-oral direct-acting antiviral regimens","volume":"90","author":"Ogata","year":"2018","journal-title":"J. Med. Virol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1136\/gut.2005.070417","article-title":"Hepatitis C virus core protein promotes proliferation of human hepatoma cells through enhancement of transforming growth factor alpha expression via activation of nuclear factor-kappaB","volume":"55","author":"Sato","year":"2006","journal-title":"Gut"},{"key":"B20","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s12038-017-9695-4","article-title":"Polymorphisms in the hepatitis C virus core and its association with development of hepatocellular carcinoma","volume":"42","author":"Sedeno-Monge","year":"2017","journal-title":"J. Biosci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1093\/molbev\/msab120","article-title":"MEGA11: molecular evolutionary genetics analysis version 11","volume":"38","author":"Tamura","year":"2021","journal-title":"Mol. Biol. Evol."},{"key":"B23","unstructured":"The world health organization. Fact sheets. Hepatitis C\n          \n          2024"},{"key":"B24","doi-asserted-by":"publisher","first-page":"5264","DOI":"10.4049\/jimmunol.167.9.5264","article-title":"Hepatitis C virus core protein inhibits human T lymphocyte responses by a complement-dependent regulatory pathway","volume":"167","author":"Yao","year":"2001","journal-title":"J. Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1006\/viro.2001.0896","article-title":"Hepatitis C virus core protein enhances FADD-mediated apoptosis and suppresses TRADD signaling of tumor necrosis factor receptor","volume":"283","author":"Zhu","year":"2001","journal-title":"Virology"}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1619865\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T05:34:58Z","timestamp":1756791298000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1619865\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,2]]},"references-count":25,"alternative-id":["10.3389\/fcimb.2025.1619865"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2025.1619865","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,2]]},"article-number":"1619865"}}